AP-2 transcription factors represent a family of three closely related and evolutionarily conserved sequence-specific DNA-binding proteins, AP-2alpha, -beta and -gamma. Subsequent studies have identified spatially and temporally regulated embryonic expression patterns in a number of different tissues including neural crest derivatives, neural, epidermal and urogenital tissues. Here, we review the current understanding of developmental defects in AP-2-deficient mice and consider regulatory functions of AP-2 in control of apoptosis, cell cycle, and gene expression. Recently, the first inherited human disorder, Char syndrome, was identified to be caused by AP-2beta missense mutations. In light of the manifold and essential functions of AP-2 proteins in cell growth, differentiation and programmed death, mutations or changes in precisely programmed expression patterns are likely to contribute to other congenital malformations or neoplastic diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0378-1119(00)00454-6DOI Listing

Publication Analysis

Top Keywords

ap-2 transcription
8
transcription factors
8
expression patterns
8
functions ap-2
8
regulatory roles
4
ap-2
4
roles ap-2
4
factors vertebrate
4
vertebrate development
4
development apoptosis
4

Similar Publications

Somatic cells can be reprogrammed into pluripotent stem cells (iPSCs) by overexpressing defined transcription factors. Specifically, overexpression of OCT4 alone has been demonstrated to reprogram mouse fibroblasts into iPSCs. However, it remains unclear whether any other single factor can induce iPSCs formation.

View Article and Find Full Text PDF

TFAP2C-mediated transcriptional activation of STEAP3 promotes lung squamous cell carcinoma progression by regulating the β-catenin pathway.

Biol Direct

December 2024

Department of Radiology, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Heping District, Shenyang, 110004, Liaoning, P. R. China.

Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is associated with the progression of several human malignancies. However, its role in lung squamous cell carcinoma (LUSC) remains unclear. We measured STEAP3 expression in LUSC cell lines and tissues.

View Article and Find Full Text PDF

Lung adenocarcinoma (LUAD) is a common type of lung cancer with complicated pathological mechanism. Transcription Factor AP-2 Alpha (TFAP2A) and Cysteine protease inhibitor 1 (CST1) are upregulated genes in LUAD samples, accordingly, we focused on clarifying the role of TFAP2A/CST1 axis in LUAD. Expression analysis was performed using real-time quantitative polymerase chain reaction and western blot.

View Article and Find Full Text PDF

TFAP2C is a key regulator of intrauterine trophoblast cell invasion and deep hemochorial placentation.

JCI Insight

December 2024

Institute for Reproductive and Developmental Sciences, Department of Pathol, University of Kansas Medical Center, Kansas City, United States of America.

Article Synopsis
  • TFAP2C is a crucial transcription factor in the development of trophoblast cells and hemochorial placentation, particularly in rats, which have a placentation process similar to humans.
  • Research using genome editing showed that completely removing TFAP2C led to prenatal death, while reducing its levels resulted in less invasion of trophoblast cells into the uterus.
  • Conditional mutagenesis revealed that targeted disruption of TFAP2C in invasive trophoblast cells hindered their invasion capacity and affected growth, indicating its important role in both early and later stages of placental development.
View Article and Find Full Text PDF

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer.

Cancer Lett

February 2025

Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, 20037, USA. Electronic address:

Breast cancer is the predominant malignancy with the majority of cases are characterized as HR+/HER2-subtype. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have shown remarkable efficacy in treating this subtype when combined with endocrine therapy, the development of resistance to these inhibitors remains a significant clinical obstacle. Hence, there is an urgent need to explore innovative therapies and decipher the underlying mechanisms of resistance to CDK4/6i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!